Asset Details
Do you wish to reserve the book?
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Do you wish to request the book?
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
Overview
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new direct-acting antiviral agents and ribavirin. Serious adverse events and treatment discontinuation were infrequent.
Approximately 184 million people worldwide have chronic hepatitis C virus (HCV) infection, and more than 350,000 people die of HCV-related liver disease each year.
1
,
2
Until recently, the standard of care for chronic HCV genotype 1 infection was a first-generation protease inhibitor, telaprevir or boceprevir, with peginterferon and ribavirin; this therapy resulted in rates of sustained virologic response of 67 to 75% among previously untreated patients.
3
,
4
The new standard of care is peginterferon and ribavirin combined with either the nucleotide nonstructural (NS) 5B polymerase inhibitor sofosbuvir or the protease inhibitor simeprevir.
5
Peginterferon-based treatment is associated with clinically significant systemic . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Antiviral Agents - adverse effects
/ Antiviral Agents - therapeutic use
/ Asthenia
/ Biological and medical sciences
/ Carbamates - adverse effects
/ Carbamates - therapeutic use
/ Diarrhea
/ Female
/ Hepatitis C, Chronic - drug therapy
/ Hepatitis C, Chronic - virology
/ Humans
/ Macrocyclic Compounds - adverse effects
/ Macrocyclic Compounds - therapeutic use
/ Male
/ Nausea
/ Patients
/ Pharmacology. Drug treatments
/ Pruritus
/ Sulfonamides - adverse effects
/ Sulfonamides - therapeutic use
